Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594763 | 0.91 | ALDH1A1 (1.00) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| Hydrochloric Acid SCHEMBL10517128 | 0.89 | ALDH1A1 (0.97) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL3417681 | 0.85 | ALDH1A1 (0.78) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL4016994 | 0.84 | ALDH1A1 (0.76) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL15314446 | 0.83 | ALDH1A1 (0.70) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL4019980 | 0.83 | KDR (0.80) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL1939629 | 0.82 | MEN1 (0.73) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL1940981 | 0.82 | ALDH1A1 (0.68) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL4019729 | 0.82 | SMN1; SMN2 (0.70) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA | |
| SCHEMBL4018024 | 0.82 | ALDH1A1 (0.68) | ALDH1A1CYP2C9SMN1; SMN2TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527326-B1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2527326-B1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-1602647-B1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-1602647-B1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1602647-A1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | FLT4, FLT1, KDR | ALDH1A1 1161/4885CYP2C9 1719/4885SMN1; SMN2 4686/4885 |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | FLT1, FLT4, PYM1 | ALDH1A1 2180/4885CYP2C9 504/4885SMN1; SMN2 3986/4885 |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | FLT1, PYM1, FLT4 | ALDH1A1 1901/4885CYP2C9 496/4885SMN1; SMN2 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.